Hi Stockrock, I was thinking the same thing, contrary to a broker briefing etc the organizers will prioritize who they allow to present. The fact that Chimeric have 2 slots is all the more encouraging. With Glioblastomer having no real SOC and such poor prognosis, there are lots of little clues here.
The real action is normally reserved for when Phase 2 trials start, but if Chimeric can give some hope we may just have an expedited program not far away.
So a possible jump before Xmas and a very interesting 2022.
Pete
CHM Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)